RELY ON GSK FLU TO HELP

PROTECT AGAINST INFLUENZA

With GSK flu vaccines, you can vaccinate all recommended patients (6 months and older) with the same 0.5-mL dose"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1-3,*

 

GSK flu vaccines are available in 0.5-mL single dose, prefilled Tip-Lok syringes. FLULAVAL QUADRIVALENT is also available in 5-mL multidose vials containing 10 doses (0.5-mL each)

  • The prefilled syringe:
  • Is color-coded for easy and quick identification
  • Contains a 2-D bar code with the NDC numbers, lot number, and expiration date to help simplify the documentation process
  • Has a color band for easy and quick identification

*One or 2 doses, depending on vaccination and age, per the annual Advisory Committee on Immunization Practices (ACIP) recommendations on prevention and control of influenza with vaccines. If 2 doses, administer each dose at least 4 weeks apart. Patients 9 years of age and older receive only 1 dose, regardless of their previous vaccination history."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1,2

Indication for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccines. FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are approved for use in persons aged 6 months and older.

CPT Codes for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

VACCINE CPT CODE NDC CODE ICD=10 CODE
FLUARIX QUADRIVALENT (Influenza Vaccine)
prefilled syringe
Package of 10
90686 NDC 58160-898-41
NDC 58160-898-52
Z23
FLULAVAL QUADRIVALENT (Influenza Vaccine)
prefilled syringe
Package of 10
90686 NDC 19515-909-41
NDC 19515-909-52
Z23
FLULAVAL QUADRIVALENT
5-mL multidose vials containing 10 doses (0.5-mL each)
Package of 1
90688 NDC 19515-900-01
NDC 19515-900-11
Z23
 

Please refer to your most up-to-date Current Procedural Terminology (CPT) and International Classification of Diseases (ICD) manuals for appropriate coding.

Administration codes will vary based on the service provided.

Contains thimerosal.

Indication for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccines. FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are approved for use in persons aged 6 months and older.

Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

  • Do not administer FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLUARIX QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common systemic adverse reactions were muscle aches, headache, and fatigue. In children 6 through 35 months of age, the most common solicited local adverse reactions were pain and redness and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children 3 through 17 years of age, the solicited local adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
  • In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients
 

Trademarks are property of their respective owners.

 

1008603R0 September 2018